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Abstract
Osteoporosis, a disease resulting in an increased risk of fracture due to compromised bone, affects 1 in 3 postmenopausal
women. Discontinuities in the microarchitecture of bone, such as trabeculae, are seen in postmenopausal osteoporosis. This
study aimed to evaluate how sleep deprivation affects the distal femur trabecular thickness of estrogen-deficient rats treated with
Zoledronate. 29 ovariectomized Wistar female rats were separated into 4 groups. The control group (C) was housed in standard
housing with a 12-hour light/dark cycle and was given an intravenous injection of 0.45 mL of 0.9% saline. The Zoledronate
group (Z) were also housed in standard conditions but given an intravenous injection of 50 ug/kg of 10% Zoledronate. The
Sleep Deprived group (SD) were given an intravenous saline injection, but were housed in chambers that did not permit sleep
for 18 hours, then moved to standard chambers that permitted 6 hours of sleep daily. The Sleep-Deprived Zoledronate group
(SDZ) was housed the same as the SD group, but was given an intravenous injection of Zoledronate. After 5 weeks, tibiae and
femora were harvested and stored at -80°C until high-resolution micro-CT was done. SDZ had improved distal femur trabecular
thickness compared to C (75.5 microns and 67 microns, respectively; p=0.0001). Multi-factor ANOVA revealed a significant
interaction between Zoledronate and sleep deprivation (p=0.0078). More research is needed to determine how this interaction
impacts executive women who often suffer from sleep deprivation and demanding professions.
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Introduction
Osteoporosis is a skeletal disorder that compromises
the strength of bone, leading to increased risk for fracture [1].
Osteoporosis can be detrimental to physical and mental health, yet
it is not a popular topic despite being identified as one of the most
significant diseases affecting human health. Women are more prone
to osteoporosis than men. One in three women over the age of 50
will experience a fracture due to osteoporosis [2]. The mechanism
of how osteoporosis affects bone is understood, but there are many
factors, including menopause, that may influence the progression
of the disease. Bone is a metabolically active tissue with
osteoblasts creating inorganic substance and osteoclasts breaking
down the inorganic substance when minerals, such as calcium,
are needed. The inorganic substance makes up 60 percent of bone
and gives it its strength and rigidity [3]. Typically, osteoblast and
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osteoclast activity is about equal, but osteoporosis is characterized
by overactive osteoclastic activity, decreased osteoblastic activity,
or a significant decrease in the activity of both [4].
Bones consist of a dense portion known as cortical bone
and an internal network of filaments known as trabecular bone
[2]. The progressive architectural deterioration of trabecular bone
can be seen by the disconnection of trabeculae due to loss of bone
mineral content. Depletion of calcium in the trabeculae is one of
the abnormalities in bone that leads to fracture in osteoporosis [2].
Trabecular bone is 3-4 times more metabolically active than cortical
bone making it a good indicator of disease as it responds quicker
than cortical bone [5]. This study focuses on trabecular thickness
because recent research suggests that the quality of bone may be a
better indicator of bone health [2]. While elderly men and women
are at a greater risk of developing osteoporosis, postmenopausal
women have the highest age-adjusted risk of fracture [1]. It is
understood that estrogens play a vital role in bone protection by
silencing osteoclasts [6]. When a woman goes through menopause
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and estrogen is no longer regularly produced, osteoclast activity
increases, and bone mineral density and bone strength decrease
[1,6]. There is no cure for postmenopausal osteoporosis, but
research is beginning to look at different medications and lifestyle
changes that could influence the disease by preventing bone
resorption.
As the population ages and retires later in life, concern
for health implications due to inadequate sleep are viable [7-9].
In 1910 average sleep duration was approximately 9 hours, but
currently, the average sleep duration among adults is 7.5 hours
[8]. With more women working now than ever before, concern
for sleep duration and sleep disturbances have become more
responsible for the health maintenance area of research [9,10].
While data has not indefinitely suggested the relationship between
sleep and osteoporosis, research suggests that lack of sleep
leads to decreased bone mineral density and strength [11,12],
particularly for postmenopausal women [10]. Another area of
study for postmenopausal osteoporosis is the pharmaceutical
role of bisphosphonates [5]. Bisphosphonates are used to slow
the progression of bone resorption by binding to hydroxyapatite
crystals, which inhibits the dissolution of the calcium phosphate
[13,14]. This binding mechanism to hydroxyapatite crystals of
bone leads to slower recruitment of osteoclasts and eventually
apoptosis [13]. There are many different kinds of bisphosphonates,
but Zoledronate is considered to be one of the most potent [13].
Zoledronate is a nitrogen-based bisphosphonate which allows for
stronger binding to bone [14]. Zoledronate has been shown to
improve the trabeculae in rats, and is generally well-tolerated in
clinical trials by humans, making it a promising choice as a treatment
for postmenopausal osteoporosis [13,15]. An annual intravenous
infusion of Zoledronate in clinical practice has been preferred
by patients compared to other bisphosphonates [16]. While it is
well understood how Zoledronate affects osteoclasts, there also
has been some research on how Zoledronate affects osteoblasts.
One study found that, for postmenopausal osteoporosis, smaller
doses such as 0.5 mg/kg body weight is ideal because it inhibits
osteoclasts without interfering in osteoblast activity [17]. Lifestyle
changes and pharmaceuticals have been studied well individually
in postmenopausal osteoporosis, but there is limited research that
predicates the implications of both.
Materials and Methods
Wistar female rats (n=29), who had a mean weight of
341g and were 8-months old, were ovariectomized by Charles
River Laboratories, Boston, MA, prior to the reception. This was
done to simulate an estrogen-deficient environment comparable
to menopause in humans. There are different strategies that
manipulate the hormonal milieu that simulate a post-menopausal
state in the animals. However, we felt that to best mimic the
cessation of ovarian function, the surgical removal of the ovaries
was the best and least complicating hormonally of the procedures.
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The rats had a 1-week adjustment period where they were placed
in their individual housing cages and were provided with Purina
rat chow and water ad libitum before the experimental period
began. A 12-hour light/dark cycle was kept during this week
where lights came on at 7:00 and turned off at 19:00. After the
week, the rats were then randomly assigned into different groups
(Table 1), including a control group (C, n=5), a sleep-deprived
group (SD, n=8), a group treated with Zoledronate (Z, n=8),
and a sleep-deprived group who also received Zoledronate for
treatment (SDZ, n=8). The University Institutional Review Board
(IRB) approved the protocol and methodology for this study. All
animal procedures, including housing, food provision, anesthesia,
surgeries, and sacrifice, were in accordance with the 2015 IACUC
guidelines.
Group

Number of
Rats

Injection Given

Sleep Deprived

C

5

0.45 mL 0.9% saline

No

SD

8

0.45 mL 0.9% saline

Yes

Z

8

50 ug/kg Zoledronate

No

SDZ

8

50 ug/kg Zoledronate

Yes

C= Control; Z= Zoledronate; SD= Sleep-deprived; SDZ= SleepDeprived Zoledronate

Table 1: Group classifications.
The groups that received Zoledronate, including the Z and
the SDZ groups, were given an intravenous injection through the
tail vein of 50 ug/kg of body weight. Only one injection was needed
for the five-week study due to the potency of Zoledronate and its
ability to bind to the hydroxyapatite crystals of bone. The C and SD
groups were given a one-time intravenous injection of 0.45mL of
0.9% saline to experience the same stress of injection as the Z and
SDZ had. After the injection, the 5-week experiment was started.
During the five-week period, sleep deprivation was simulated
by the Modified Multiple Platform Method (MMPM) [18]. We
modified rectangular acrylic fish tanks (144cmx44cmx44cm); one
for the SD group and one for the SDZ group, that were fitted with
14 circular platforms that had a diameter of 6.5cm (Figure 1). The
platforms were 10cm away from each other. Each tank was filled
with room-temperature water until the water reached 1cm below
the top of the platforms (Figure 1). Purina rat chow and drinking
water were available in the tanks at all times. The food and fresh
water were placed in accessible containers positioned at the top of
the tanks and away from the standing water and platforms. These
tanks allowed the rats to move around, but if they fell asleep, they
would fall into the water and be woken up. Therefore, these rats
were unable to maintain a normal sleep cycle. The SD and SDZ
rats participated in 1 of 3 different sleep cycles each day (Table 2).
The sleep cycle was assigned using a random number generator.
Each day at 14:00, the rats were moved into the MMPM tanks.
Volume 4; Issue 02

Citation: Nolte E, Frisch F, Lopez O (2020) The Physiological Interaction of Sleep Deprivation and Zoledronate on Distal Femur Trabecular Thickness of Ovariectomized
Rats. Arch Epidemol 4: 145. DOI: 10.29011/2577-2252.100045

Then between 07:00 and 09:00, they were moved to a tank with wood chip bedding, food and water, and that allowed sleep in the
darkness. This provided the rats with 5-7 hours of sleep per day, depending on the cycle permitted (Table 3). The C and Z groups were
housed under standard conditions and permitted 12 hours of light/dark.

Figure 1: Modified multiple platform tank.
Sleep Cycle

Start Time

End Time

Time Awake (hrs)

Time Allowed for Sleep (hrs)

SC1

14:00

9:00

19

5

SC2

14:00

8:00

18

6

SC3

14:00

7:00

17

7

A random number generator would select one of the three sleep cycles listed above, daily. The rats would be placed in the MMP tank during the
wake time, then they would be moved to a standard chamber for sleeping.

Table 2: Sleep cycles.
Day

Time Awake (hr.)

Time Asleep (hr.)

Sleep Cycle

1

17

7

3

2

18

6

2

3

19

5

1

4

17

7

3

5

18

6

2

6

19

5

1

7

18

6

2

8

17

7

3

9

19

5

1

10

17

7

3

11

17

7

3

3
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12

17

7

3

13

19

5

1

14

17

7

3

15

17

7

3

16

17

7

3

17

17

7

3

18

19

5

1

19

19

5

1

20

19

5

1

21

18

6

2

22

19

5

1

23

18

6

2

24

19

5

1

25

18

6

2

26

19

5

1

27

19

5

1

28

17

7

3

29

19

5

1

30

18

6

2

31

18

6

2

32

18

6

2

33

18

6

2

34

17

7

3

35

17

7

3

Amount of sleep permitted as indicated by the sleep cycle. Sleep cycle was determined by a random number generator. The amount of wake time
was spent in the MMP tank.

Table 3: Daily Sleep/Wake Times.
At the end of 5 weeks, blood and tissue samples were collected and frozen prior to death. The rats were sedated with 0.001 mL/g
of ketamine/atropine/xylazine cocktail. Following sedation, all animals were decapitated and exsanguinated. Blood was obtained and
centrifuged at 14,000 RPM for 5 minutes at 5°C and frozen at -80°C for studies not reported in this paper. Femora and tibiae were
harvested, wrapped in saline-soaked gauze, and frozen at -80°C. The right tibiae and femora of each rat were shipped to Novartis
Institute for Biomedical Research. Ex vivo DEXA scans ex vivo high-resolution micro-Computed Tomography (micro-CT) and
peripheral Quantitative computed tomography (pQCT) of the distal and midshaft femur (Figure 2). The scans and data were then sent
to Chapman University for analysis. This report is limited to the femora data, which was statistically analyzed with the use of multiple
comparisons tests and ANOVA in RStudio.
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Group

Average Distal Femur Trabecular
Thickness (microns)

Control (C)

67 ± 0.721

Zoledronate (Z)

68.375 ± 0.240

Sleep-Deprived (SD)

68.375 ± 0.188

Sleep-Deprived +
Zoledronate (SDZ)

75.5*** ± 0.400

The average distal femur trabecular thickness of each group including
standard error. A significant difference was determined with ANOVA
between the Control and Sleep-Deprived Zoledronate groups.
***P=0.0001

Table 4: Average Distal Femur Trabecular Thickness of Each
Group.

Discussion
Figure 2: Depiction of Location of micro-CT and pQCT of the
Distal Femur Ex vivo location of the micro-CT and pQCT of the
rat’s distal femur.
Results
Data from the micro-CT suggested an increase in distal
femur trabecular thickness between the C and SDZ groups (67,
75.5 microns, respectively; p=0.0001) (Table 4). Additionally,
sleep deprivation seemed to improve distal femur trabecular
thickness between the Z and SDZ groups (68.375, 75.5 microns,
respectively, p=0.00007). Because the sleep deprivation seemed to
improve distal femur trabecular thickness, a multi-factor ANOVA
was conducted and revealed a significant interaction between the
treatment and the amount of sleep the rats received (p=0.0078)
(Figure 3).

Figure 3: Interaction plot between Treatment and Housing.
Estimates from an ANOVA model with treatments as main
effect and an interaction term as covariates (p=0.0078, R2 = 0.612).
5
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It was expected that sleep deprivation would cause thinner
trabeculae in the distal femora of ovariectomized rats and that
treatment with Zoledronate would improve this. However, data
suggested that the sleep-deprived groups had a greater distal
femur trabecular thickness. Because the SDZ group had a much
greater increase in distal femur trabecular thickness than the Z
group, an interaction plot was created using ANOVA. The plot
revealed a possible physiological interaction between the amount
of sleep and the use of Zoledronate. Further studies are needed to
determine the mechanism behind the physiological interaction, but
results could have a profound impact on the use of Zoledronate in
modern society where many people are getting less sleep because
of work Demands. While the animals in this study were provided
lab chow ad libitum, future studies should include the evaluation
of the amount of food daily ingested. It is widely observed that
food intake may be modified by the stress of decreased sleep [19].
This could be a factor in the metabolism of bone tissue. Another
consideration that should be addressed is the sample size of this
study. Though there was significance between the C and SDZ
groups, the small sample size of 32 rats may not have been robust
enough to provide more illumination into the effects of this protocol.
Other studies that have tested Zoledronate in ovariectomized rats
have had at least 80 rats [20-22]. The duration of this study was
carefully considered, with it being estimated that the relative age
for humans during a postmenopausal period over 1 year is equal to
11.8 days for rats [23]. Given this information, it was determined
that a 5-week trial for the rats would be approximately a 3-year
trial for postmenopausal women, which is a common timeline for
bisphosphonate clinical trials.
While the MMPM has been a commonly used technique
for sleep deprivation in animal studies, it may have stimulated
osteoblast activity in this study. One study that looked at the effects
of exercise on ovariectomized rats found that the rats who were
Volume 4; Issue 02
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forced to run each day had significantly greater bone mass especially
in the trabecular bone [24]. In humans, this phenomenon (Wolff’s
Law) causes improved bone quality and increased bone mineral
content when the bone experiences greater mechanical stress over
time [25]. In future studies, consideration should be taken of the
type of bisphosphonate used and the timing of the injection. While
Zoledronate is one of the most potent bisphosphonates, there
have been recent studies that suggest diluting it with propanol or
parathyroid hormone has been more effective than Zoledronate by
itself [26,27].

Conclusion
Executive women, who often suffer from sleep deprivation,
are a growing subclass of postmenopausal patients suffering from
osteoporosis. This study attempted to evaluate Zoledronate as an
intervention to reduce bone loss. While these data suggested a
significance in the SDZ group compared to the C group, a trial of
longer duration and greater sample size may be more illuminating.
Rats held in the sleep deprivation tanks may have been using muscles
which may have stimulated osteoblasts. Overall, Zoledronate may
have a protective effect in sleep-deprived ovariectomized rats and
suggests promise as a therapeutic intervention for postmenopausal
executive women with osteoporosis.

Acknowledgments
The investigative team appreciates the funding and support by
Novartis Int. AG. We recognize and appreciate the laboratory
assistance from Dr. Kenneth Sumida, Dr. Eric Sternlicht and Dr.
Milton Greenberg.

Authorship Confirmation Statement
Authors of this work are in compliance with the definition
of Author, as defined by the International Committee of
Medical Journal Editors. This manuscript is submitted with the
understanding that they have neither been published, nor are under
consideration for publication elsewhere.
Authors Disclosure Statements
Competing Interests: There are no competing interests with
respect to this study.
Personal Financial Interests: There are no financial interests
associated with this study or with any of the authors.
Funding: There was funding support for the analysis of bone
samples from Novartis, but no gain or loss in financial status is or
will be incurred with the publication of this article.
Other Competing Interests: There are no competing interests,
which compromise the integrity or objectivity of this study.

6
Arch Epidemiol, an open access journal
ISSN: 2577-2252

Funding Statement
Support for the analysis of trabecular thickness and bone
integrity was provided by Novartis International, AG, Basel,
Switzerland.

References
1.

Klibanski A, Adams-Campbell L, Bassford TL, Blair SN, Boden SD, et
al. (2001) Osteoporosis prevention, diagnosis, and therapy. Journal of
the American Medical Association 285: 785-795.

2.

Bartl R, Frisch B (2004) Osteoporosis: Diagnosis, Prevention, Therapy:
A Practical Guide for all Physicians-from Pediatrics to Geriatrics.
Springer.

3.

Feng X (2009) Chemical and biochemical basis of cell-bone matrix
interaction in health and disease. Curr Chem Biol 3: 189-196.

4.

Guido G, Scaglione M, Fabbri L, Ceglia MJ (2009) The “osteoporosis
disease”. Clin Cases Miner Bone Metab, 6: 114-116.

5.

Avioli LV (Ed.) (2000) The osteoporotic syndrome: Detection,
prevention, and treatment. Elsevier.

6.

Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, et al. (2009)
Estrogens maintain bone mass by regulating expression of genes
controlling function and life span in mature osteoclasts. Ann N Y Acad
Sci 1173: E31-E39.

7.

Bonnet MH, Arand DL (1995) We are chronically sleep deprived. Sleep
18: 908-911.

8.

Spiegel K, Leproult R, Van Cauter E (1999) Impact of sleep debt on
metabolic and endocrine function. The Lancet 354: 1435-1439.

9.

Chen G, Chen L, Wen J, Yao J, Li L, et al. (2014) Associations between
sleep duration, daytime nap duration, and osteoporosis vary by sex,
menopause, and sleep quality. J Clin Endocrinol Metab 99: 2869-2877.

10. Fu X, Zhao X, Lu H, Jiang F, Ma X, et al. (2011) Association between
sleep duration and bone mineral density in Chinese women. Bone 49:
1062-1066.
11. Sasaki N, Fujiwara S, Yamashita H, Ozono R, Teramen K, et al. (2016)
Impact of sleep on osteoporosis: sleep quality is associated with bone
stiffness index. Sleep medicine 25: 73-77.
12. Specker BL, Binkley T, Vukovich M, Beare T (2007) Volumetric
bone mineral density and bone size in sleep-deprived individuals.
Osteoporos Int 18: 93-99.
13. Fleisch H (2000) Bisphosphonates in bone disease: from the laboratory
to the patient. Elsevier.
14. Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms
of action of bisphosphonates: similarities and differences and their
potential influence on clinical efficacy. Osteoporosis international 19:
733-759.
15. Räkel A, Boucher A, Ste-Marie LG (2011) Role of zoledronic acid in
the prevention and treatment of osteoporosis. Clinical interventions in
aging 6: 89.
16. Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C (2013)
Intravenous bisphosphonates for postmenopausal osteoporosis:
safety profiles of zoledronic acid and ibandronate in clinical practice.
Clinical drug investigation 33: 117-122.

Volume 4; Issue 02

Citation: Nolte E, Frisch F, Lopez O (2020) The Physiological Interaction of Sleep Deprivation and Zoledronate on Distal Femur Trabecular Thickness of Ovariectomized
Rats. Arch Epidemol 4: 145. DOI: 10.29011/2577-2252.100045
17. Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, et al. (2009)
High-dose zoledronic acid impacts bone remodeling with effects on
osteoblastic lineage and bone mechanical properties. Clin Cancer Res
15: 5829-5839.
18. Machado RB, Hipólide DC, Benedito-Silva AA, Tufik, S (2004) Sleep
deprivation induced by the modified multiple platform technique:
quantification of sleep loss and recovery. Brain res 1004: 45-51.

23. Sengupta P (2013) The Laboratory Rat: Relating Its Age With Human’s.
Int J Prev Med 4: 624-630.
24. Li L, Chen X, Lv S, Dong M, Zhang L, et al. (2014) Influence of
exercise on bone remodeling-related hormones and cytokines in
ovariectomized rats: a model of postmenopausal osteoporosis. PloS
one 9: e112845.

19. Everson CA (1995) Functional consequences of sustained sleep
deprivation in the rat. Behav Brain Res 69: 43-54.

25. Ruff C, Holt B, Trinkaus E (2006) Who’s afraid of the big bad
Wolff?:“Wolff’s law” and bone functional adaptation. Am J Phys
Anthropol 129: 484-498.

20. Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, et al. (2003)
Long-term zoledronic acid treatment increases bone structure and
mechanical strength of long bones of ovariectomized adult rats. Calcif
Tissue Int 72: 519-527.

26. Khajuria DK, Razdan R, Mahapatra DR (2014) The combination
therapy with zoledronic acid and propranolol improves the trabecular
microarchitecture and mechanical property in an rat model of
postmenopausal osteoporosis. J of Osteoporos 2014: 586431.

21. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long‐
term protective effects of zoledronic acid on cancellous and cortical
bone in the ovariectomized rat. Journal of Bone and Mineral Research
23: 544-551.

27. Rhee Y, Won YY, Baek MH, Lim SK (2004) Maintenance of Increased
Bone Mass After Recombinant Human Parathyroid Hormone (1‐84)
With Sequential Zoledronate Treatment in Ovariectomized Rats. J
Bone Miner Res 19: 931-937.

22. Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal
timing of a single dose of zoledronic acid to increase strength in rat
fracture repair. J Bone Miner Res 22: 867-876.

7
Arch Epidemiol, an open access journal
ISSN: 2577-2252

Volume 4; Issue 02

